Mpex Pharmaceuticals Gains $27.5M

San Diego-based Mpex Pharmaceuticals said Tuesday that the firm has raised $27.5M in a Series D financing round. The firm, which is developing antibiotics, said that the round was led by Investor Growth Capital. Other investors in the firm included RiverVest Venture Partners, SV Life Sciences, HBM BioVentures, Aberdare Ventures and Adams Street Partners. The firm said that those investors have made commitments to additional closing, which will bring the round to $40.0M. Mpex is developing a aerosol formulation of the antibiotic levofloxacin, targeted at the treatment of chronic respiratory infections such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). More information »